Abstract
The limited scope of therapeutic drug-level monitoring in cancer chemotherapy results from the often complex biochemical mechanisms that contribute to antineoplastic activity and obscure the relationships among drug serum levels and therapeutic benefits. Moreover, new agents for cancer chemotherapy are being introduced at a more rapid rate than for the treatment of other diseases, although the successful application of therapeutic drug-level monitoring may require several years of intensive study of the significance of serum drug levels. However, drug level monitoring can be of considerable value during phase I clinical trials of new antineoplastic agents in order to assess drug metabolism, bioavailability, and intersubject variability; these are important parameters in the interpretation of clinical studies, but have no immediate benefit to the patient. High performance liquid chromatography (HPLC) probably represents the most versatile and easily adaptable analytical technique for drug metabolite screening (1). HPLC may therefore now be the method of choice during phase I clinical trials of antineoplastic drugs. For example, within a single week we developed an HPLC assay—using a C18 reverse-phase column, UV detection, and direct serum injection after protein precipitation—for the new radiosensitizer, misonidazole (2).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Sadée, W., and Beelen, G. C. M., Drug Level Monitoring, Wiley, New York, 1980.
Marques, R. A., Stafford, B., Flynn, N., and Sadée, W., J. Chromatogr. 146, 163 (1978).
Wasserman, T. H., Philips, T. L., Johnson, R. L., Gomer, C. J., Lawrence, G. A., Sadée, W., and Marques, R. A., Int. J. Rad. Oncol. Biol. Phys. 5, 775 (1979).
Sadée, W., Therap. Drug Monitor., in press.
Bleyer, W. A., Cancer Treat. Rev. 4, 87 (1977).
Tattersall, M. H. N., Parker, L. M., Pitman, S. W., and Frei, E. III, Cancer Chemother. Rep. (Part 3) 6, 25 (1975).
Stoller, R. G., Hande, K. R., Jacobs, S. A., Rosenberg, S. A., and Chabner, B. A., N.E.J. Med. 297, 630 (1977).
Frei, E. III, Jaffe, N., Tattersall, M. H. N., Pitman, S., and Parker, L., N.E.J. Med. 292, 846 (1975).
Dedrick, R. L., Zaharko, D. S., and Lutz, R. J., J. Pharm. Sci. 62, 882 (1973).
Goldman, D., Cancer Treat. Rep. (Part 3) 6, 51 (1975).
Canfell, C. and Sadée, W., Cancer Treat. Rep., in press (1980).
Watson, E., Cohen, J. L., and Chan, K. K., Cancer Treat. Rep. 62, 381 (1978).
Wisnicki, J. L., Tong, W. P., and Ludlum, D. B., Cancer Treat. Rep. 62, 529 (1978).
Lankelma, J., and Poppe, H., J. Chromatogr. 149, 587 (1978).
Nelson, J. R., Harris, B. A., Decker, W. J., and Farquhar, D., Cancer Res. 37, 3970 (1977).
Cohen, J. L., and Brown, R. E., J. Chromatogr. 151, 237 (1978).
Jones, R. A., Buckpitt, A. R., Londer, H. H., Myers, C. E., Chabner, B. A., and Boyd, M. R., Bull. Cancer 66, 75 (1979).
Au, J. L., Wu, A. T., Friedman, M. A., and Sadée, W., Cancer Treat. Rep. 63, 343 (1979).
Au, J. L., and Sadée, W., Cancer Res. 39, 4289 (1979).
Baurain, R., Deprez, D., De-Campeneere, and Trouet, A., Analyt. Biochem. 94, 112 (1979).
Peters, J. H., and Murray, Jr., J. F., J. Liquid Chromatogr. 2, 45 (1979).
Staffan, E., J. Chromatogr. 149, 225 (1978).
Langone, J. J., and van Vunakis, H., Biochem. Med. 12, 283 (1975).
Hulhoven, R., and Desager, J. P., J. Chromatogr. 125, 369 (1976).
Shiu, G. K., Goehil, T. J., and Pitlick, W. H., J. Pharm. Sci. 68, 232 (1979).
Terry, T. K., Belime, R. J., and Brooke, D., J. Pharm. Sci. 68, 172 (1979).
Chang, S. Y., Alberts, D. S., Melvick, L. R., Walson, P. D., and Salman, S. E., J. Pharm. Sci. 5, 679 (1978A).
Furner, R. L., Mellet, L. B., Brown, R. K., and Duncan, G., Drug Metab. Dispos. 4, 577 (1976).
Ding, T. L., and Benet, L. Z., J. Chromatogr. Biomed. Applic. 163, 281 (1979).
Day, J. L., Tterlikkis, L., Niemann, R., Mobley, A., and Spikes, C., J. Pharm. Sci. 67, 1027 (1978).
Weinkam, R. J., and Shiba, D. A., Life. Sci. 22, 937 (1978).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 The Humana Press, Inc.
About this protocol
Cite this protocol
Sadée, W., El Sayed, Y.M. (1981). Antineoplastic Drugs. In: Kabra, P.M., Marton, L.J. (eds) Liquid Chromatography In Clinical Analysis. Biological Methods. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-404-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-60327-404-3_9
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-026-8
Online ISBN: 978-1-60327-404-3
eBook Packages: Springer Book Archive